CRVS
Corvus Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.65
+1.37%Sep 30, 2026, 20:05 UTC
Corvus Pharmaceuticals began enrollment in a Phase 1b clinical trial of soquelitinib for the treatment of patients with hidradenitis suppurativa.
Source:Aug 27, 2026, 11:30 UTC
Corvus Pharmaceuticals announced the publication in Blood of final Phase 1 data from its soquelitinib Phase 1/1b T cell lymphoma trial, supporting ongoing registration trials.
Source:Aug 6, 2026, 00:00 UTC
Corvus Pharmaceuticals reported a net loss of $18.0 million for Q2 2026, compared to a net loss of $8.0 million in Q2 2025, with diluted EPS of -$0.19.